JPRN-UMIN000011467已完成未知
Evaluation of efficacy of erlotinib in patients with untreated, EGFR mutation positive, untreated-locally advanced NSCLC. - Efficacy of erlotinib in patients with untreated-locally advanced NSCLC.
agasaki Thoracic Oncology Group0 个研究点目标入组 10 人开始时间: 2013年8月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Having interstitial pneumonitis 2)Uncontrolable complications
研究者
相似试验
招募中
2 期
A phase II study of erlotinib for patients with pretreated non-small cell lung cancer with brain metastasis and sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000002861Shizuoka General Hospital Respiratory center24
已完成
2 期
Phase II study of erlotinib monotherapy for patients with advanced stage of non-small cell lung cancer, undetectable epidermal growth factor receptor (EGFR) mutations by PNA LNA PCR clamp method, but positive immuno-staining with anti-EGFR mutation-specific antibodies.on-small cell lung cancerJPRN-UMIN000014299Dept. of Respiratory Medicine, Osaka Police Hospital7
已完成
2 期
Phase II study of erlotinib monotherapy for patients with untreated advanced non-small cell lung cancer, poor performance status and positive EGFR mutation status (OSAKA-LCSG1304)JPRN-UMIN000011473OSAKA-LCSG23
已完成
2 期
A phase II study of Erlotinib for patients previously treated non-small cell lung cancer with epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004563Fukushima Medical University, cancer center26
已完成
2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild typeadvanced or recurrent non-small-cell lung cancerJPRN-UMIN000008398Gunma Uninersity Hospital30